Biomedical Radiation Sciences

Akiram Therapeutics is a Swedish clinical-stage biotechnology company specializing in the development of next-generation targeted radiopharmaceuticals for aggressive and incurable cancers. Spun out from research at Uppsala University's Biomedical Radiation Sciences division, the company leverages expertise in radiation sciences and antibody engineering to create precision therapies. Its lead candidate, 177Lu-AKIR001, is a radiolabeled antibody targeting the CD44v6 marker, which is highly expressed in several difficult-to-treat malignancies. Akiram is currently advancing its pipeline into clinical trials, with a primary focus on anaplastic thyroid cancer and other solid tumors with high unmet medical needs.